New hope for smoldering myeloma: daratumumab doses tested
NCT ID NCT02316106
First seen Apr 26, 2026 · Last updated May 06, 2026 · Updated 4 times
Summary
This study tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that can turn into active cancer. The goal was to see which dose schedule works best to control the disease and prevent it from progressing. Participants received daratumumab infusions on different timings, and researchers measured how many achieved a complete response or had their disease get worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Little Rock, Arkansas, United States
-
Study site
Jacksonville, Florida, United States
-
Study site
West Palm Beach, Florida, United States
-
Study site
Atlanta, Georgia, United States
-
Study site
Boston, Massachusetts, United States
-
Study site
Ann Arbor, Michigan, United States
-
Study site
St Louis, Missouri, United States
-
Study site
Hackensack, New Jersey, United States
-
Study site
New York, New York, United States
-
Study site
Chapel Hill, North Carolina, United States
-
Study site
Cincinnati, Ohio, United States
-
Study site
Columbus, Ohio, United States
-
Study site
Philadelphia, Pennsylvania, United States
-
Study site
Nashville, Tennessee, United States
-
Study site
Seattle, Washington, United States
-
Study site
Box Hill, Australia
-
Study site
Concord, Australia
-
Study site
Melbourne, Australia
-
Study site
Woodville South, Australia
-
Study site
Calgary, Alberta, Canada
-
Study site
Edmonton, Alberta, Canada
-
Study site
Toronto, Ontario, Canada
-
Study site
Brno, Czechia
-
Study site
Hradec Králové, Czechia
-
Study site
Prague, Czechia
-
Study site
Lille, France
-
Study site
Nantes, France
-
Study site
Paris, France
-
Study site
Pierre-Bénite, France
-
Study site
Rennes, France
-
Study site
Berlin, Germany
-
Study site
Chemnitz, Germany
-
Study site
Essen, Germany
-
Study site
Heidelberg, Germany
-
Study site
Mainz, Germany
-
Study site
München, Germany
-
Study site
Tübingen, Germany
-
Study site
Würzburg, Germany
-
Study site
Haifa, Israel
-
Study site
Jerusalem, Israel
-
Study site
Petah Tikva, Israel
-
Study site
Tel Aviv, Israel
-
Study site
Amsterdam, Netherlands
-
Study site
Rotterdam, Netherlands
-
Study site
Utrecht, Netherlands
-
Study site
Nizhny Novgorod, Russia
-
Study site
Petrozavodsk, Russia
-
Study site
Ryazan, Russia
-
Study site
Saint Petersburg, Russia
-
Study site
Ankara, Turkey (Türkiye)
-
Study site
Antalya, Turkey (Türkiye)
-
Study site
Izmir, Turkey (Türkiye)
-
Study site
Samsun, Turkey (Türkiye)
-
Study site
Cardiff, United Kingdom
-
Study site
Nottingham, United Kingdom
-
Study site
Southampton, United Kingdom
-
Study site
Surrey, United Kingdom
Conditions
Explore the condition pages connected to this study.